Charlie Porter Research Grant
The Charlie Porter Research Grant was created by twilight in 2010 and rasied $80,000 for UofM research scientists
to support promising new research relating to the etiology, treatment and cure of Acute Myeloid
Leukemia (AML) in children; the grant was awared in 2012.
Charlie Porter's Story
Charles Eldon Porter, "Charlie" was born June 17, 2004:
8 lbs 13 oz., 21 inches long and was a perfect, healthy little baby. On January 3, 2006, however,
he was diagnosed with AML, Acute Myeloid Leukemia and was admitted to Vanderbilt Children’s Hospital
in Nashville, TN. He went through five rounds of chemotherapy ending in June of 2006. After almost
seven full months in the hospital he was released in July 2006 and was a happy, healthy 2-year-old.
On December 28, 2006 Charlie relapsed and was readmitted to inpatient care. He went through another
difficult chemotherapy regimen to prepare him for a bone marrow transplant. On March 16, he received
a bone marrow transplant from an anonymous, matched donor through a national registry. All was going
to plan until he got severe graft-versus-host disease that did not respond to steroids. He was admitted
back to the hospital and spent two more months in the hospital trying to fight. Charlie passed away
on June 28, 2007. He had just turned 3 years old.
Funding and Requirements
With the guidance of our distinguished Medical Advisory Board, The Twilight Benefit
Foundation invites proposals for innovative new research projects. The Medical Board reviews applications
and recommends the most promising projects to the Twilight Benefit Board of Directors. We carefully monitor
each grant allocation. All funds that will be used by the receiving institution will be allocated according
to the Twilight Benefit Foundation’s directives. We require mid-term and end-of-project reports, along with
a budget expense report prior to the final disbursement of the grant.
How the Charlie Porter Research Grant Worked
1. Any doctor who was at the Ph.D., D.O. or MD level who was involved in innovative research toward finding the causes
and cure for Acute Myeloid Leukemia (AML) in children could apply.
2. Each application was then reviewed by our Medical Advisory Committee.